Abstract
Lung cancer is associated with poor prognosis. The aim of this study was to evaluate the clinical usefulness of HMGB-1 (high-mobility group protein B1) and TGF-β (transforming growth factor beta) in patients with advanced non-small cell lung cancer (NSCLC). We studied 45 patients with NSCLC prior to chemotherapy, 23 patients with Besnier-Boeck-Schaumann (BBS) disease (sarcoidosis), and 15 healthy volunteers. HMGB-1 and TGF-β levels were measured in serum and BALF samples using ELISA method. A higher serum HMGB-1 and TGF-β levels were in NSCLC patients compared with the other groups. TGF-β concentration in BALF was significantly higher in NSCLC than in healthy controls (p = 0.047) but lower than in BBS (p = 0.016). Serum HMGB-1 in NSCLC correlated with age and gender while its level in BALF was associated with distant metastasis. A higher levels of HMGB-1 in the serum of NSCLC patients with progressive disease was linked with shorter overall survival and disease-free survival. We found a positive correlation between HMGB-1 and TGF-β in BALF of IIIB NSCLC group and overall survival (p = 0.04; p = 0.003). Our findings confirmed that the measurement of HMGB-1 and TGF-β levels in serum and BALF of patients with NSCLC prior to treatment may have clinical usefulness and predict poor prognosis.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Costabel U, Hunninghake GW (1999) ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J 14:735–737
Domagała-Kulawik J, Hoser G, Safianowska A, Grubek-Jaworska H, Chazan R (2006) Elevated TGF-beta1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer. Arch Immunol Ther Exp 54:143–147
Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–148
Ebina M, Taniguchi H, Miyasho T, Yamada S, Shibata N, Ohta H, Hisata S, Ohkouchi S, Tamada T, Nishimura H, Ishizaka A, Maruyama I, Okada Y, Takashi K, Nukiwa T (2001) Gradual increase of high mobility group protein b1 in the lungs after the onset of acute exacerbation of idiopathic pulmonary fibrosis. Pulm Med 2011:916486
Guo Y, Liu Y, Tan PQ, Li G, Su ZW, Tian YQ, Qiu YZ (2012) Expressions and clinical significance of high mobility group box-1 mRNA and protein in laryngeal squamous cell carcinoma tissues and serum. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 47:487–490
Hamada N, Maeyama T, Kawaguchi T, Yoshimi M, Fukumoto J, Yamada M, Yamada S, Kuwano K, Nakanishi Y (2008) The role of high mobility group box1 in pulmonary fibrosis. Am J Respir Cell Mol Biol 39:440–447
Han J, Tang FM, Pu D, Xu D, Wang T, Li W (2014) Mechanisms underlying regulation of cell cycle and apoptosis by hnRNP B1 in human lung adenocarcinoma A549 cells. Tumori 100:102–111
Hirakata Y, Kitamura S (1996) Elevated serum transforming growth factor beta 1 level in primary lung cancer patients with finger clubbing. Eur J Clin Invest 26:820–823
Hou YL, Chen H, Dong ZH, Xue CJ, Wu YF, Luo HX, Wu YC, Li CH (2013) Clinical significance of serum transforming growth factor-β1 in lung cancer. Cancer Epidemiol 37:750–753
Kowalska A, Puścińska E, Czerniawska J, Goljan-Geremek A, Czystowska M, Rozy A, Chorostowska-Wynimko J, Górecka D (2010) Markers of fibrosis and inflammation in exhaled breath condensate (EBC) and bronchoalveolar lavage fluid (BALF) of patients with pulmonary sarcoidosis – a pilot study. Pneumonol Alergol Pol 78:356–362
Liu F, Zhang Y, Peng Z, Gao H, Xu L, Chen M (2012a) High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J Transl Med 10:135
Liu L, Ge D, Ma L, Mei J, Liu S, Zhang Q, Ren F, Liao H, Pu Q, Wang T, You Z (2012b) Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer. J Thorac Oncol 7:1091–1100
Pittet JF, Koh H, Fang X, Iles K, Christiaans S, Anjun N, Wagener BM, Park DW, Zmijewski JW, Matthay MA, Roux J (2013) HMGB1 accelerates alveolar epithelial repair via an IL-1β- and αvβ6 integrin-dependent activation of TGF-β1. PLoS One 16:e63907
Semrau S, Zettl H, Hildebrandt G, Klautke G, Fietkau R (2014) Older patients with inoperable non-small cell lung cancer: long-term survival after concurrent chemoradiotherapy. Strahlenther Onkol 12:1125–1132
Shang GH, Jia CQ, Tian H, Xiao W, Li Y, Wang AH, Dong L, Lin DJ (2009) Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med 103:1949–1953
Smolarczyk R, Cichoń T, Jarosz M, Szala S (2012) HMGB1-its role in tumor progression and anticancer therapy. Postepy Hig Med Dosw 66:913–920
Stenmark MH, Cai XW, Shedden K, Hayman JA, Yuan S, Ritter T, Ten Haken RK, Lawrence TS, Kong FM (2013) Combining physical and biologic parameters to predict radiation-induced lung toxicity in patients with non-small-cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys 84:e217–e222
Suda K, Kitagawa Y, Ozawa S, Saikawa Y, Ueda M, Abraham E, Kitajima M, Ishizaka A (2006) Serum concentrations of high-mobility group box chromosomal protein 1 before and after exposure to the surgical stress of thoracic esophagectomy: a predictor of clinical course after surgery? Dis Esophagus 19:5–9
Sun KK, Ji C, Li X, Zhang L, Deng J, Zhong N, Wu XY (2013) Overexpression of high mobility group protein B1 correlates with the proliferation and metastasis of lung adenocarcinoma cells. Mol Med Rep 7:1678–1682
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (2004) Pathology and genetics of tumours of the lung, pleura, thymus and heart, World Health Organization classification of tumours. ARC Press, Lyon, pp 10–33
Van de Wiele C, Vande Vyver F, Debruyne C, Philippé J, van Meerbeeck JP (2008) FDG uptake by the bone marrow in NSCLC patients is related to TGF-beta but not to VEGF or G-CSF serum levels. Eur J Nucl Med Mol Imaging 3:519–522
Vazquez PF, Carlini MJ, Daroqui MC, Colombo L, Dalurzo ML, Smith DE, Grasselli J, Pallotta MG, Ehrlich M, Bal de Kier Joffé ED, Puricelli L (2013) TGF-beta specifically enhances the metastatic attributes of murine lung adenocarcinoma: implications for human non-small cell lung cancer. Clin Exp Metastasis 30:993–1007
Wang C, Fei G, Liu Z, Li Q, Xu Z, Ren T (2012) HMGB1 was a pivotal synergistic effector for CpG oligonucleotide to enhance the progression of human lung cancer cells. Cancer Biol Ther 13:727–736
Wang JL, Wu DW, Cheng ZZ, Han WZ, Xu SW, Sun NN (2014) Expression of high mobility group box – B1 (HMGB-1) and matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer (NSCLC). Asian Pac J Cancer Prev 15:4865–4869
Acknowledgments
We are indebted to Dr. Maria Ossolińska for the help with the ELISA assessment. KJ participated in this study within the doctoral support program co-funded by the European Union Social Funds for the academic year 2013–2014.
Conflicts of Interest
The authors had no conflicts of interest to declare in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Jakubowska, K., Naumnik, W., Niklińska, W., Chyczewska, E. (2015). Clinical Significance of HMGB-1 and TGF-β Level in Serum and BALF of Advanced Non-Small Cell Lung Cancer. In: Pokorski, M. (eds) Respiratory Carcinogenesis. Advances in Experimental Medicine and Biology(), vol 852. Springer, Cham. https://doi.org/10.1007/5584_2015_115
Download citation
DOI: https://doi.org/10.1007/5584_2015_115
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-16921-7
Online ISBN: 978-3-319-16922-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)